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Background: The aim of this study is to outline a general process for assessing the feasibility of performing a valid
network meta-analysis (NMA) of randomized controlled trials (RCTs) to synthesize direct and indirect evidence for
alternative treatments for a specific disease population.
Methods: Several steps to assess the feasibility of an NMA are proposed based on existing recommendations. Next,
a case study is used to illustrate this NMA feasibility assessment process in order to compare everolimus in
combination with hormonal therapy to alternative chemotherapies in terms of progression-free survival for women
with advanced breast cancer.
Results: A general process for assessing the feasibility of an NMA is outlined that incorporates explicit steps to
visualize the heterogeneity in terms of treatment and outcome characteristics (Part A) as well as the study and
patient characteristics (Part B). Additionally, steps are performed to illustrate differences within and across different
types of direct comparisons in terms of baseline risk (Part C) and observed treatment effects (Part D) since there is a
risk that the treatment effect modifiers identified may not explain the observed heterogeneity or inconsistency in
the results due to unexpected, unreported or unmeasured differences. Depending on the data available, alternative
approaches are suggested: list assumptions, perform a meta-regression analysis, subgroup analysis, sensitivity
analyses, or summarize why an NMA is not feasible.
Conclusions: The process outlined to assess the feasibility of an NMA provides a stepwise framework that will help
to ensure that the underlying assumptions are systematically explored and that the risks (and benefits) of pooling
and indirectly comparing treatment effects from RCTs for a particular research question are transparent.
Keywords: Advanced breast cancer, Everolimus, Chemotherapy, Network meta-analysis, Progression-free survival,
Systematic literature review, Feasibility assessmentBackground
Network meta-analyses (NMA) are increasingly being per-
formed to inform decision-making regarding the com-
parative efficacy and safety of alternative treatments [1]. In
order to determine the comparative efficacy or safety of a
new treatment using a NMA it is necessary to establish
the relevant comparators. Generally, the indication for the* Correspondence: scope@mapigroup.com
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reproduction in any medium, provided the ornew treatment and the way in which the new treatment is
expected to be used in clinical practice will determine the
comparators of interest. In some cases the comparators
are explicitly defined by reimbursement agencies for a
technology appraisal, which is the case in the United
Kingdom where the National Institute for Health and
Care Excellence (NICE) develops a final scope based on
a stakeholder consultation process [2].
In order to inform decision-making it is necessary to
assess whether it is feasible to perform a valid NMA to
compare the new treatment with usual care based ontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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any NMA, the validity of such analysis relies on whether
there are systematic differences among the studies in-
cluded in the network across treatment comparisons,
especially patient or disease characteristics that are treat-
ment effect modifiers [3-6]. Although there is guidance
available regarding the underlying principles of an NMA,
there is a need for a more structured process that incorpo-
rates both clinical and methodological expertise to assess
the feasibility of performing a valid NMA [7]. The aim of
this study is to outline a general process for assessing the
feasibility of performing a valid NMA. A case study is used
to illustrate the feasibility of performing an NMA to com-
pare everolimus in combination with hormonal therapy to
alternative chemotherapies in terms of progression-free
survival (PFS) for women with advanced breast cancer
(ABC).
The first section presents general steps for assessing
the feasibility of a NMA. Next, the case study is pre-
sented in terms of the background, the identification
and selection of trials, the method for the systematic re-
view and analysis, and the results of the feasibility as-
sessment and NMA. Readers are encouraged to use our
application of these rules to our clinical example as a
case study in applying our process to a possible research
question and may envision ways to apply it to their own
review.
Methods
Assessing feasibility of a network meta-analysis
In the absence of trials involving a direct comparison of
interventions, an indirect comparison can provide valu-
able evidence for the relative treatment effects between
competing interventions [5,8-14]. Even when the results
of the direct evidence are conclusive, combining them
with the results of indirect estimates in a mixed treat-
ment comparison may yield more precise estimates as a
greater evidence base is considered [8,10,12]. If the avail-
able evidence base consists of a network of interlinked
multiple RCTs involving treatments compared directly
or indirectly or both, it can be synthesized by means of
NMA [4,8,11,13,14]. Since randomization of patients
does not hold across trials in a network of RCTs, there
might be differences across treatments that may com-
promise the validity of a NMA. It can be expected that
there will always be some degree of variation in patient
characteristics across studies. If these characteristics are
effect modifiers of the relative treatment effects of inter-
est then there will be heterogeneity in the evidence base.
If there is an imbalance in relative treatment effect
modifiers across comparisons, then the transitivity and
consistency assumptions do not hold and some or all of
the estimates of the NMA will be biased [5,9,11]. There-
fore, it is important to assess whether there are differencesin study and patient characteristics across comparisons
that affect the summary measures of treatment effects
(that is, odds ratio or hazard ratio) for the interventions of
interest relative to an overall reference treatment. (Note:
Differences in prognostic factors that are not also treat-
ment effect modifiers do not impact the validity of the
analysis).
A general process for assessing the feasibility of an
NMA is outlined in Figure 1, which builds upon the exist-
ing recommendations regarding NMA [5,6,11]. Initially,
steps to visualize the clinical heterogeneity in terms of
treatment and outcome characteristics (Part A) as well as
the study and patient characteristics (Part B) are proposed
[7]. Next, steps are suggested to assess differences within
and across the direct pairwise comparisons in terms of
baseline risk (Part C) and observed treatment effects (Part
D) since there is a risk that the treatment effect modifiers
identified may not explain the observed heterogeneity or
inconsistency in the results due to unexpected, unreported
or unmeasured differences.
The proposed process for the feasibility assessment of
an NMA is recommended to be specified in the system-
atic review protocol and statistical analysis plan. It is rec-
ommended to develop a parsimonious list of potential
treatment effect modifiers for the study and patient cha-
racteristics based on prior knowledge before beginning
the systematic review and feasibility assessment that will
help guide Part B [6]. The process also acknowledges
that some additional differences may be identified that
act as treatment effect modifiers, which could be prede-
fined in terms of a process to identify outliers. In some
cases a modification to the statistical analysis plan may
be required. For example, decisions regarding pooling
different treatment doses or regimens (Part A) may be
challenging to pre-specify in the statistical analysis plan
without having identified the relevant evidence.
It is recommended that the decision to perform an
NMA should be based primarily on clinical judgment of
whether differences among studies may affect the com-
parisons of treatments or make some comparisons in-
appropriate [11]. However, an evaluation of baseline risk
and heterogeneity (or inconsistency) in observed treat-
ment effects in Part C and Part D may help identify ana-
lyses to adjust for differences [4,15]. Therefore, it is
suggested to pre-specify the types of analyses that will
be used to explore heterogeneity and/or inconsistency,
which may include the use of a random effects model,
unrelated means model [4], exclusion of specific studies
that are outliers (using pre-defined criteria), node split-
ting [16], or the inclusion of inconsistency factors [17-19].
Ultimately, using this process will help to ensure that the
risks (and benefits) of pooling and indirectly comparing
treatment effects reported in RCTs for a particular re-
search question are clearly documented [11].
Figure 1 Overview of process to assess the feasibility of performing a valid network meta-analysis. *Planned meta-regressions in previous
steps should be considered when assessing whether there is sufficient data for a meta-regression. It may be possible to perform separate meta-
regressions per potential treatment effect modifier, although this should be clearly stated as a limitation.
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making a judgment on whether or not there is sufficient
data to explain or adjust for differences in potential treat-
ment effect modifiers using a meta-regression. Although
there is no clear threshold regarding the number of data
points required to perform a meta-regression, Gagnier
et al. refer to a general rule of thumb which suggests
that there should be close to ten trials when working
with summary or aggregate patient data (or ten individ-
uals per variable, when working with pooled or individ-
ual patient data), but also caution that fewer studies
may be associated with more heterogeneity, and more
variables explored may be associated with a higher type
1 error rate [7]. Therefore, the number of data points
should be considered against the number of parameters
included in the meta-regression model. Generally, when
these types of meta-regressions are based on aggregate
study level data, it is assumed that the effect of the co-
variate is constant across the different treatments, which
is recommended for most cases given the limited data
available [20]. While accounting for study-level factors
using these types of models is advised, the risk of eco-
logical bias should be recognized when adjusting for dif-
ferences in patient characteristics in the absence of
individual patient level data [21,22].Case study
Everolimus is indicated for the treatment of hormone
receptor-positive, human epidermal growth factor recep-
tor type 2 negative (HER2-) ABC, in combination with
exemestane (EXE), in postmenopausal women without
symptomatic visceral disease after recurrence or pro-
gression following a non-steroidal aromatase inhibitor
(NSAIs) [23].
The phase III RCT BOLERO-2 demonstrated that
everolimus plus EXE more than doubled median PFS
compared with placebo plus EXE while still maintaining
quality of life in ABC patients (estrogen receptor posi-
tive (ER+) and HER2-) who recurred or progressed dur-
ing or after NSAIs [24-27]. Additionally, the phase II
TAMRAD trial demonstrated the efficacy of everolimus
in combination with tamoxifen (TAM) in comparison to
TAM alone [28].
For women with ER+ ABC, guidelines recommend
endocrine therapy as the preferred option even in the
presence of visceral disease. If there is evidence of endo-
crine resistance or rapidly progressive disease requiring
a fast response then chemotherapy is recommended [29].
Figure 2 illustrates the current treatment pathway for
ER+ patients with ABC and also outlines the anticipated
use of everolimus in the treatment sequence. Everolimus
Figure 2 Anticipated treatment pathway including everolimus for advanced breast cancer. Adapted from NICE Pathways, Advanced Breast
Cancer: endocrine therapy; Accessed July 22 2013 from: [32].
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apy which can delay treatment with chemotherapy and
has been described as ‘a step change in treatment’ [30].
Consequently the comparison of everolimus in combin-
ation with hormonal therapy versus chemotherapy is of
interest and was defined as a comparator of interest by
NICE [31].
Identification and selection of studies
A systematic literature search was performed in March
2013 to identify published RCTs evaluating the efficacy
of treatment regimens for patients with postmenopausal
ABC (stage III or IV) who were treated with everolimus,
alternative hormonal therapies or alternative chemothe-
rapies to facilitate an indirect comparison of everoli-
mus versus chemotherapy. Medline, Medline In-Process,
EMBASE and Cochrane databases were searched by using
a predefined search strategy with terms relevant to ABC,
RCTs and the comparisons of interest (see search strategy
in Additional file 1).
Two reviewers independently evaluated each identified
study against the following predetermined criteria:
Population: postmenopausal women with ABC (locally
ABC (stage III) or metastatic breast cancer (stage IV)).
Interventions: everolimus (in combination with
hormonal therapy) and chemotherapies including
capecitabine, vinorelbine, paclitaxel, docetaxel, nab-paclitaxel, doxorubicin, epirubicin, pegylated liposomal
doxorubicin and eribulin.
Comparisons Step 1: everolimus (in combination with
hormonal therapy) versus hormonal therapy alone;
EXE versus TAM; hormonal therapy versus
chemotherapy.
Comparisons Step 2: chemotherapy identified in Step 1
versus any chemotherapies of interest; Comparison of
alternative hormonal therapies identified in Step 1.
Outcomes: Kaplan Meier curves reporting PFS, time to
progression (TTP) or time to failure (TTF).
Study design: phase II or III RCTs.
Although the target population for everolimus was
based on the BOLERO-2 trial, which included only ER+
HER2- patients with prior NSAI treatments, the scope
of the population was defined more broadly in order to
capture all available evidence for trials comparing hor-
monal therapy to chemotherapy.
For each identified study that met the selection cri-
teria, details were extracted on study design, study popu-
lation characteristics and interventions. For all studies,
the reported PFS Kaplan-Meier curves were digitized for
each treatment arm (DigitizeIt v1.6.1). The data set was
created on the basis of extracted progression proportions
(including PFS, TTP or TTF), which were used to calcu-
late the incident number of events for each interval and
patients at risk at the beginning of that interval [33].
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randomization and tumor progression or death from any
cause, with censoring of patients who are lost to follow-up,
where progression events include an increase in tumor size
and/or the development of new tumors according to stan-
dardized criteria such as Response Evaluation Criteria in
Solid Tumors. TTP is typically defined as the time elapsed
between randomization and tumor progression, with cen-
soring of patients who die or are lost to follow-up. Finally,
TTF may be defined as the time from randomization until
progression, relapse, or death from any cause, although
this may vary. PFS, TTP and TTF are not always labelled
or defined consistently in different trials [34].
Assessing the feasibility of a network meta-analysis for
postmenopausal women with advanced breast cancer
The process outlined in Figure 1 was applied in order to
assess whether a NMA was feasible to indirectly com-
pare everolimus (in combination with hormonal therapy)
to alternative chemotherapies in terms of PFS for post-
menopausal women with ABC. The following potential
treatment effect modifiers were identified a priori based
on clinical expertise: hormone receptor status (HR-status),
prior hormonal therapy, prior chemotherapy, visceral me-
tastases, performance status and age. For parts A and B,
network diagrams illustrating the structure of the network
as well as differences in outcome definitions and potential
treatment effect modifiers were developed. For parts C
and D the baseline risk and heterogeneity in observed
treatment effects were also illustrated to facilitate an as-
sessment of the differences within and across direct treat-
ment comparisons.
A Bayesian NMA was planned using the methodology
introduced by Ouwens et al. and Jansen et al. to syn-
thesize and indirectly compare the published PFS Kaplan-
Meier curves for each treatment and RCT [33,35,36].
With this approach, the PFS of patients over time of the
interventions compared in a trial is modeled with para-
metric survival functions and the difference in the shape
and scale parameters of these functions between interven-
tions is synthesized and indirectly compared across trials.
The best fitting first order fractional polynomial model
was selected [36] using the deviance information criteria
(DIC) [37,38]. Additional details on these models and




A stepwise process was used to select the relevant RCTs
and to assess the feasibility of a NMA (Figure 3 presents
the flow chart, while Additional file 2: Table S1 pre-
sents all included trials, their respective authors, years
of publication and interventions) [24-28,40-64]. Based onthe first step of the systematic literature review three
RCTs were identified comparing hormonal therapies to
chemotherapies (TAM versus cyclophosphamide + doxo-
rubicin (CD), megestrol acetate (MA) versus cyclophos-
phamide +methotrexate + fluorouracil (CMF), and MA
versus mitoxantrone (MZ) [40,43,64]). These RCTs were
connected to three RCTs identified comparing everoli-
mus + TAM to TAM, everolimus + EXE to EXE, and TAM
to EXE [24,25,28,59-62]. Therefore, it was possible to de-
velop a network of connected RCTs based on these six
RCTs. However, this network, based on step 1, only al-
lowed for an indirect comparison of everolimus (plus
hormonal therapy) to the chemotherapies CD and CMF.
Since these chemotherapy combinations were not of
interest, the network was extended to include an add-
itional 14 RCTs comparing alternative chemotherapies
of interest [41,42,45-47,49,50,54,57-60,63,65,66].
Additionally, four RCTs comparing alternative hor-
monal therapies in the network were included to streng-
then the network (comparing MA to TAM or EXE)
[43,48,51-53,55,56] based on the final step outlined in
the systematic review protocol. Although the objective
of this network was not to compare the efficacy of alter-
native hormonal therapies, these RCTs provided add-
itional connections between trials evaluating everolimus
and those treatments required to link to chemotherapies
of interest. As was done for this case study, we would
advise the utilization of the most ‘comprehensive’ evi-
dence base in the initial feasibility assessment. However,
for trials comparing treatments that are not directly of
interest for the decision-problem it is important to con-
sider that the additional value of evidence should be
weighed against the risk of introducing additional hetero-
geneity (or inconsistency) to the network. Exploring the
impact of a broader evidence base for the network was
not the purpose of this study, although this is an import-
ant issue that has been considered by Cooper et al. [67].
Is there a connected network comparing the treatments
of interest for the outcome of interest?
The available RCTs formed a connected network of evi-
dence in order to indirectly compare everolimus in
combination with hormonal therapy to the relevant che-
motherapies, which is illustrated in Additional file 3:
Figure S1. However, the indirect comparison of everoli-
mus (in combination with hormonal therapy) versus any
of the chemotherapies of interest is mediated by at least
four different treatment comparisons. The studies in-
cluded between 48 to 769 patients per study, with five
studies including fewer than 100 patients. Based on the
number of relatively small RCTs available and the large
‘degree of separation’ in the network pathway connecting
the treatments of interest, the estimates of the indirect
treatment were expected to be very uncertain.
Figure 3 Flow chart illustrating the study selection process for the systematic review. CT, chemotherapy; EVE, everolimus; EXE, exemestane;
HT, hormonal therapy; RCTs, randomized controlled trials; TAM, tamoxifen.
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comparisons for the outcome of interest?
Part A - The treatment (doses/ schedules) or outcome
definitions that are expected to modify relative
treatment effect
Some differences in the treatment doses and/or sched-
ules were identified, which are summarized in Additional
file 4: Table S2. Since there were a limited number of
RCTs included per treatment (ranging from one up toseven RCTs for doxorubicin), a meta-regression was not
deemed to be feasible to adjust for differences in treat-
ment doses. However, the RCTs that were most different
in terms of treatment dose were planned to be excluded
in a sensitivity analysis based on clinical expertise. In
the ‘All Evidence’ base case analysis the different treat-
ment doses were grouped together assuming that there
would have been no differences in outcomes (beyond
sampling error) between the different treatments within
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treated. A comparison between the base case analysis
and the sensitivity analysis excluding specific treatment
doses may be possible to explore the impact of this
assumption.
Differences across the RCTs and treatment compari-
sons were also identified in terms of the outcome defin-
ition. Eleven RCTs reported TTP, seven RCTs reported
PFS and six RCTs reported TTF (Figure 4). The network
included 24 trials evaluating two treatment arms of in-
terest in terms of 17 different treatments. Therefore, the
simplest arm-based (fixed effect) model assuming a con-
stant hazard ratio to synthesize the network of studies
would include 40 parameters (24 baseline effects for
each study and (17–1 = 16) treatment effects), whereas
an analysis based on reported hazard ratios would pro-
vide only 24 data points. A meta-regression to adjust for
differences in the PFS definitions was planned but may
not be feasible given the limited amount of data; there-
fore, a sensitivity analysis was planned to exclude RCTs
within the network evaluating TTF [40,44,48,50,63,68],
which may differ the most from TTP and PFS.Figure 4 Network of included RCTs for the base case PFS based on K
cyclophosphamide + doxorubicin; CMF, cyclophosphamide +methotrexate
hormonal therapy; MA, megestrol acetate; PFS, progression-free survival; PLPart B – The distribution of study or patient characteristics
that are expected to modify relative treatment effects
(defined a priori)
RCTs in the network were generally multicenter open-
label trials evaluating women with either advanced or re-
current breast cancer and the study design was considered
to be broadly comparable despite some single center trials
[43,64]. A summary of the risk of bias across the trials is
presented in Additional file 5: Figure S2 and an overview
of the risk of bias per RCTs is presented in Additional
file 6: Figure S3. Given the limited variation in the blind-
ing of patients across the RCTs, it was determined that
there was insufficient data to assess this assumption in
terms of a meta-regression. Similarly, since so many of the
RCTs were open-label, a sensitivity analysis to exclude
these studies was deemed not to be feasible. Therefore, in
order to synthesize the trials in the ‘All Evidence’ base case
network, it would be necessary to assume that differences
in the study design or quality did not act as a treatment ef-
fect modifier, which may bias the treatment estimates.
Differences were identified in terms of the distribution
of patient characteristics within and across the treatmentaplan Meier curves: hormone receptor status. CD,
+ 5-fluorouracil; CT, chemotherapy; ER, estrogen receptor; HT,
D, pegylated liposomal doxorubicin; RCT, randomized controlled trial.
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fect modifiers for ER status (Figure 4), exposure to prior
hormonal therapies [see Additional file 7: Figure S4], ex-
posure to prior chemotherapies [see Additional file 8:
Figure S5] and visceral metastases (Figure 5). Although a
meta-regression to adjust for each of these differences in
a separate analysis may be possible, since there were
such a large number of studies where the distribution of
patient characteristics was not reported, it is likely that
these adjustments will be inadequate. Sensitivity analyses
to exclude specific studies were not planned given the
substantial variation in the differences across the treat-
ment comparisons and the reliance of the network on
several older studies comparing hormonal therapy to
chemotherapy that did not report several patient charac-
teristics. Therefore, there is a risk that treatment esti-
mates based on an NMA of the base case network will
be biased, as the results would only be valid if it can be
assumed that differences in the distribution of patient
characteristics do not act as treatment effect modifiers
(that is, ER status, exposure to prior hormonal therapies,Figure 5 Network of included RCTs for the base case PFS based on K
doxorubicin; CMF, cyclophosphamide +methotrexate + 5-fluorouracil; CT, c
progression-free survival; PLD, pegylated liposomal doxorubicin; RCT, randoexposure to prior chemotherapies and visceral metasta-
ses). Differences in terms of performance status and age
were considered less prominent and are summarized in
Table 1. Given the variation observed, sensitivity ana-
lyses to exclude outlier studies were planned.
Beyond the differences identified based on the pre-
defined potential treatment effect modifiers, differences
were also detected in terms of post-menopausal status,
HER2 status, and types of prior hormonal therapies, which
are also summarized in Table 1. Sensitivity analyses were
planned to exclude studies that were outliers in terms of
post-menopausal status [48]. However, no sensitivity ana-
lyses were possible in terms of HER2 status, as only the
everolimus trials reported this characteristic. Similarly,
sensitivity analyses were not planned for differences iden-
tified in terms of the type of prior hormonal therapy given
the limited number of studies that reported this infor-
mation: patients in the everolimus trials received prior
aromatase inhibitor (letrozole or anastrozole), whereas pa-
tients in other studies received an estrogen receptor an-
tagonist (TAM) or this information was not reported.aplan Meier curves: visceral metastases. CD, cyclophosphamide +
hemotherapy; HT, hormonal therapy; MA, megestrol acetate; PFS,
mized controlled trial.
Table 1 Overview of variation in potential treatment effect modifiers in the RCTs included in the progression-free survival analysis


















Comparisons Baselga 2012, BOLERO-II [24] EXE vs. EVE + EXE 724 100% 0% 100% NR 56% 96% 62 100% 100% AIa
Bachelot 2012, [28] TAMRAD TAM vs. EVE + TAM 111 100% NR 100% 24% 48% 92% 63 100% 95% AIa
HT vs. HT Paridaens 2008, [60-62]
EORTC-10951
EXE vs. TAM 371 89% 5% 22% 33% 47% 87% 62 100% NR TAM
HT vs. HT Kaufmann 2000 [51-53] EXE vs. MA 769 68% 32% 100% 17% 59% NR 65 100% NR TAM
HT vs. HT Muss 1985, [55,56]
POASTUDY
TAM vs. MA 136 58% 34% 3% 10% 37% 79% 62 100% NR NR
HT vs. HT Ingle 1982 [48] TAM vs. MA 55 NR NR 0% NR 44% 79% 49 48% NR NA
HT vs. HT Gill 1993 [44] TAM vs. MA 118 40% 45% 0% 0% 53% NR NR 100% NR NA
HT vs. CT ANZBCTG 1986 [40] TAM vs. CD 226 16% 73% NR NR 38% 60% NR 100% NR NR
HT vs. CT Dixon 1992 [43] MA vs. MZ 60 20% 10% 100% 0% 30% 100% 61 100% NR TAM
HT vs. CT Villalon 1993 [64] MA vs. CMF 48 NR NR NR 0% NR NR NR 83% NR NR
CT vs. CT Cowan 1991 [68] MZ vs. DOX 237 40% 13% 55% 59% 67% 73% NR 83% NR NR
CT vs. CT Henderson 1989 [47] MZ vs. DOX 325 30% 20% 52% 63% 40% 71% NR 85% NR NR
CT vs. CT Katsumata 2009, [50]
JCOG9802
CD vs. DOC 293 35% 8% 100% 0% 67% 95% 54 NR NR NR
CT vs. CT O'Shaughenessy 2001 [58] CMF vs. CAP 93 NR NR 91% 0% 66% NR 70 100% NR 49% TAM
CT vs. CT Chan 1999 [65] DOX vs. DOC 326 NR NR 71% 58% 76% NR NR NR NR NR
CT vs. CT Paridaens 2000 [59] DOX vs. PAC 331 24% 37% 74% 0% 75% 91% 55 NR NR NR
CT vs. CT Sledge 2003, [63] E1193 DOX vs. PAC 453 46% 29% 60% 0% 61% 85% 58 NR NR NR
CT vs. CT Bontenbal 1998, [42] EORTC
10811
DOX vs. EPI 232 NR NR 36% 98% 42% 73% 56 92% NR NR
CT vs. CT O'Brien 2004 [57] DOX vs. PLD 509 40% 37% NR 0% 56% 89% 58 62% NR NR
CT vs. CT Jones 2005 [49] DOC vs. PAC 449 56% 44% 60% 58% NR NR 56 88% NR NR
CT vs. CT Beuselinck 2010, [41] BSMO DOC vs. PAC 70 42% NR NR 81% 78% 84% NR 100% NR NR
CT vs. CT Gradishar 2009 [45,46] DOC vs. Nab-PAC 148 NR NR NR 0% 91% 97% NR 81% NR NR
CT vs. CT Yardley 2009 [66] DOC vs. L-DOX 102 63% 0% 60% 0% 87% 91% 63 NR NR NR
CT vs. CT Meier 2008 [54] DOC vs. VIN 120 60% NR NR 90% 90% 74% 60 NR NR NR
aAI, aromatase inhibitors included letrozole and anastrozole. CD, cyclophosphamide + doxorubicin; CMF, cyclophosphamide +methotrexate + fluorouracil; CAP, capecitabine; CT, chemotherapy; DOC, docetaxel; DOX,
doxorubicin; ECOG, European Co-operative Oncology Group; ER, estrogen receptor; EPI, epirubicin; EVE, everolimus; EXE, exemestane; HER2, human epidermal growth factor receptor type 2; HT, hormonal therapy;
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the relative treatment effect
The RCTs in the network were conducted between 1978
and 2012. Therefore, there may be a risk that differences
attributable to changes in clinical practice over time could
influence the treatment effect, which may justify adjusting
for baseline risk. However, in this network there was no
clear placebo or standard of care to provide a common
treatment arm in order to assess baseline risk. TAM was
selected as the baseline comparator of the analysis given
the proximity to everolimus and the larger number of
RCTs compared to TAM in the network. Additional file 9:
Figure S6 presents the individual study results for PFS as
extracted from the Kaplan Meier curves per treatment for
the included RCTs. This illustration suggests that there is
some variation in the baseline risk for TAM, although it
is unclear whether these differences are associated with
baseline risk. Since there was no clear reference treat-
ment that was common to all (or most) comparisons in
the network, adjusting for differences in baseline risk in
a meta-regression was not considered. Furthermore, no
clear outliers were identified based on the observed vari-
ation in baseline risk. Consequently, an NMA combining
the RCTs in the base case is at risk of bias due to differ-
ences in clinical practice over time, although the role of
baseline risk on the treatment effect is not clear.
Part D - Differences in observed treatment effects
Additional file 10: Figure S7 presents the PFS results by
study. In the network of evidence there are only four
comparisons that are supported by multiple RCTs. For
the three RCTs comparing MA versus TAM [44,48,56]
the differences consistently favor TAM although there is
some variation in the magnitude of the observed effect.
For the comparison of doxorubicin versus MZ, both
RCTs suggest that there is very little difference in PFS
between the treatments [47,68], with doxorubicin show-
ing a slightly more favorable result. However, in the
comparison of paclitaxel versus doxorubicin the study
by Paridaens et al. [59,60] favors doxorubicin over pacli-
taxel, whereas the study by Sledge et al. [63] suggests
the opposite, although differences in both cases are min-
imal. Similarly, for the comparison of paclitaxel versus
docetaxel the study by Jones et al. [49] suggests doce-
taxel is favored over paclitaxel, whereas the study by
Beuselinck et al. [41] found very little difference between
the treatments and the curves cross each other more
than once. Therefore, within the pairwise comparison
some heterogeneity was identified, primarily with respect
to the chemotherapy comparisons, although the differ-
ences were not substantial. The between-study standard
deviation resulting from the analysis was 0.41 (95% cre-
dible interval (CrI): 0.22, 0.81), which suggests signifi-
cant between study heterogeneity was present that wasconfirmed by the improved model fit of the random ef-
fects model over the fixed effects model based on the
DIC (FE = 3729.0; RE = 3684.0). These results confirm
the presence of heterogeneity in the network.
Given that there are three ‘closed loops’ within the net-
work, an unrelated means (UM) analysis [4] was planned
to assess whether results for each pairwise comparison
were consistent with the estimates from the NMA which
included both the direct and indirect evidence. However,
due to the limited amount of data in the network, it was
expected that there would be insufficient power to de-
tect a significant difference between the NMA and UM
models.
Results of the NMA
Results are presented in terms of PFS curves over time
for each intervention (Figure 6) and the PFS hazard ra-
tios (over time) for each intervention relative to TAM
[see Additional file 11: Figure S8]. Based on the PFS sur-
vival functions, the mean PFS was estimated at 20 and
40 months, respectively (Table 2). The mean PFS reflects
the area under the PFS survival curve to the left of each
time point up until the corresponding follow-up time
point of interest. This represents a summary measure of
PFS that does not require the curves to be fully extra-
polated (that is, up until all patients have progressed).
Additional detail regarding the interpretation of survival
outcomes in the context of a NMA based on fractional
polynomial models is discussed by Cope et al. [69]. All
figures summarizing the results are presented up until
40 months, at which point a majority of the patients are
expected to have progressed. Given the large number of
curves, the treatments are grouped depending on the
comparison: chemotherapies of interest, the connecting
chemotherapies (that is, RCTs that connect hormonal
therapies to chemotherapies), everolimus in combination
with hormonal therapy, and hormonal therapy.
Results suggest that the hazard ratios for vinorel-
bine, CD, docetaxel, doxorubicin, PLD, paclitaxel, nab-
paclitaxel, CMF, epirubicin, capecitabine and liposomal
doxorubicin increased over time versus TAM, whereas the
hazard ratios for everolimus + TAM, everolimus + EXE,
EXE, MA and MZ were relatively constant over time ver-
sus TAM. Hence, a proportional hazard assumption is not
valid, and, as such, results based on a constant hazard ra-
tio model should be interpreted with caution. Based on
the NMA using Weibull time-varying hazard ratio model,
everolimus in combination with either EXE or TAM is ex-
pected to be at least as good as the alternative chemother-
apies of interest. However, given the differences identified
in terms of treatment doses, outcome definitions and po-
tential treatment effect modifiers, there is a risk that the
indirect treatment estimates are potentially biased. Adjust-
ing for baseline risk did not provide a useful approach for
Figure 6 All Evidence network: PFS over time for each group of treatments as obtained with random effects Weibull network meta-
analysis model with time-varying hazard ratios (up to 40 months). CD, cyclophosphamide + doxorubicin; CMF, cyclophosphamide +
methotrexate + 5-fluorouracil; CT, chemotherapy; HT, hormonal therapy; MA, megestrol acetate; PFS, progression-free survival; PLD, pegylated
liposomal doxorubicin.
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including TAM, and identifying potential inconsisten-
cies in the network was challenging given the low power
and the number of comparisons included in the closed
loops.Table 2 All evidence network: mean PFS per intervention and
alternatives













Nab paclitaxel 10.10 (
Liposomal doxorubicin 6.66 (
Vinorelbine 7.55 (
Exemestane + Everolimus 12.21 (
Tamoxifen + Everolimus 10.85 (
*As obtained with random effects Weibull network meta-analysis model with time-v
CD, cyclophosphamide + doxorubicin; CMF, cyclophosphamide +methotrexate + flu
liposomal doxorubicin; 95% CrI, 95% credible interval.Discussion
The aim of this study was to propose a more structured
process to assess the feasibility of performing a valid
NMA. The suggested procedure builds on existing rec-
ommendations for NMAs and provides more explicitdifference in expected PFS for everolimus versus
95% CrI Mean PFS at 40 months* 95% CrI
(5.31; 8.29) 7.05 (5.48; 9.11)
4.55; 12.63) 9.04 (4.60; 16.47)
5.00; 11.91) 7.98 (5.00; 12.50)
4.51; 10.38) 7.42 (4.54; 11.85)
5.85; 15.76) 10.23 (5.85; 20.36)
3.43; 13.03) 7.91 (3.43; 16.01)
4.37; 12.45) 7.93 (4.37; 13.30)
3.96; 12.09) 7.36 (3.96; 12.80)
2.53; 12.17) 6.16 (2.53; 12.96)
5.03; 16.67) 9.96 (5.04; 22.43)
3.78; 11.90) 7.11 (3.78; 12.50)
3.09; 13.56) 7.15 (3.09; 15.12)
5.42; 15.75) 10.15 (5.42; 18.33)
3.12; 12.00) 6.66 (3.12; 12.38)
2.99; 14.28) 7.60 (2.99; 17.71)
6.21; 16.98) 14.14 (6.25; 26.72)
5.16; 15.59) 13.62 (5.36; 24.79)
arying hazard ratios and no covariates.
orouracil; MA, megestrol acetate; PFS, progression-free survival; PLD, pegylated
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at each step. The process is designed to be stepwise, with
the initial stages focused on the clinical differences (that
is, related to treatments, outcomes, study design and pa-
tients) and the later stages focused on evaluating the ob-
served outcomes. Parts A and B involve an assessment of
the clinical heterogeneity in terms of treatment, outcome,
study and patient characteristics. Parts C and D involve an
evaluation of the differences within and across the direct
pairwise comparisons in terms of baseline risk and ob-
served treatment effects. This means that it may be de-
cided that an NMA is not feasible after the initial stage,
without having assessed heterogeneity or inconsistency. If
the decision is made to complete the full feasibility assess-
ment, the available data should be illustrated and the
underlying assumptions should be clearly stated, thereby
improving the transparency and facilitating an interaction
between methodologists and clinicians. While this process
does not avoid the need for subjective decisions, it allows
decision-makers or researchers to critically analyze each
choice as well as to update an analysis using a different ap-
proach without necessarily having to repeat the entire
process.
The final step of any NMA is to critically assess the
findings. Recently guidance to facilitate this process has
been developed, including the International Society for
Pharmacoeconomics and Outcome Research ‘instrument
to assess the relevance and credibility of a NMA’ [70], a
‘reviewer’s checklist’ for evidence synthesis for treatment
efficacy used in decision-making [71], as well guidance
on ‘how to use an article reporting (Grading of Recom-
mendations and Evaluation (GRADE)) a multiple treat-
ment comparison meta-analysis’ [72]. Additionally, the
GRADE process to assess meta-analyses has recently
been updated by Cochrane to address the NMA more
specifically. The current process for assessing the feasi-
bility does not provide explicit guidance regarding the
types of tools to be used for this process, but there
seems to be a shared focus on some key principles that
should be assessed, including the magnitude of the
treatment effects, the uncertainty in the estimates and
the risk of bias due to the quality of the RCTs as well as
any differences in the distribution of treatment effect
modifiers across direct treatment comparisons.
In the case study comparing everolimus to alternative
chemotherapies in terms of PFS for women with ABC
the feasibility of the NMA was determined to be limited.
Although it was possible to achieve a connected network
of RCTs for the comparisons of interest, differences were
identified in terms of the treatment doses and the out-
come definitions, which could be explored by excluding
outlier studies. However, differences were also identified
with respect to the pre-defined treatment effect modi-
fiers as well as post-hoc differences in specific patientcharacteristics that were not possible to explore based
on the available data. Some variation in baseline risk
within trials including TAM was observed, as was some
heterogeneity in the treatment effects, whereas the in-
consistency was challenging to assess in this network. In
conclusion, given the differences identified in potential
treatment effect modifiers which cannot be explored,
there is a substantial risk that differences in these po-
tential treatment effect modifiers may introduce bias,
threatening the overall validity of the NMA, which re-
flects a limitation of the available data. Despite the lim-
ited feasibility of the case study, it was decided to
perform the NMA for exploratory purposes. The point
estimates from the analysis suggest that everolimus in
combination with EXE or TAM is at least as efficacious
as the chemotherapies of interest in terms of PFS. How-
ever, the comparison of interest is linked through several
indirect treatment comparisons, which led to substantial
uncertainty in the treatment estimates. We would advise
caution regarding the interpretation of the results given
the conclusion of the feasibility assessment.
The decision to proceed with the NMA can be criti-
cized in light of the findings from the feasibility assess-
ment. However, there is an immediate need for evidence
from decision-makers given the context of the research
question, as well as a potential long-term gap in the evi-
dence, which suggests this NMA may provide the best
available evidence. For example, findings from the cur-
rent NMA may provide a more robust result based on
the available evidence in comparison to a previous ‘naïve
chained indirect analysis’ that multiplied a pooled hazard
ratio for chemotherapy versus endocrine therapy (from
the meta-analysis by Wilken et al.) by a hazard ratio for
everolimus in combination with TAM versus TAM (based
on the TAMRAD trial and assumed to be the same as
everolimus in combination with EXE to EXE) [73]. Al-
though there is a risk that results of the NMA will be
over-interpreted, we would argue that the purpose of the
feasibility assessment is to ensure that the underlying as-
sumptions and limitations of the NMA are clearly com-
municated. Further, NMA results may help to quantify the
between-study variability (and possibly the inconsistencies
in the evidence base in some cases), thereby providing a
more complete exploration of heterogeneity, which may
generate further hypotheses [7]. Finally, in some cases, re-
sults of an NMA may actually help to trigger a response
from clinical experts regarding the plausibility of the un-
derlying assumptions, which may otherwise be more diffi-
cult to reveal. In general, we would advise consideration
regarding the value of exploratory analyses against the risk
of over-interpretation.
The case study of everolimus for women with ABC
provides a unique opportunity to illustrate the challenges
associated with evaluating the feasibility of a NMA given
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practice. In such cases where a new treatment introduces
an additional step in the traditional treatment pathway, it
may be necessary to compare the current treatment path-
way (in the absence of the new treatment) with the antici-
pated treatment pathway (including the new treatment).
When there are no trials available comparing the current
treatment pathway to the anticipated treatment pathway,
this often implies a comparison between the new treat-
ment and the usual treatment used as the ‘next step’ in
the treatment pathway. However, by definition, a new
treatment that delays the next step in a treatment pathway
is designed to target a less severe population. Conse-
quently, there is an inherent risk that the patient charac-
teristics of the RCTs available for the new treatment are
not comparable to those patients in the RCTs evaluating
the ‘next step’. Additionally, as new treatments become
more targeted based on genetic differences in receptors, it
may be difficult to compare new trials evaluating a subset
of patients with older trials including a full population
(that may not report the receptors of interest). Despite
these limitations, it may be decided to combine the direct
and indirect results and to perform an NMA given the ab-
sence of evidence regarding the comparison of interest
and the need for clinicians and health technology bodies
such as NICE to make decisions. The tendency to perform
an NMA in the context reinforces the importance of the
feasibility assessment process. Moreover, this case study
identifies a clear need for a new trial comparing the evero-
limus to chemotherapy, or a comparison of the alternative
treatment pathways with and without everolimus (that is,
everolimus followed by chemotherapy versus placebo fol-
lowed by chemotherapy).
One of the main limitations of the case study is that
overall survival was not assessed. The current study fo-
cused on PFS given the available data for everolimus at
the time of the feasibility assessment. In comparison to
overall survival, PFS is not susceptible to confounding
by differences in subsequent treatments across the stud-
ies, although there is a risk of assessment bias with PFS.
Therefore, overall survival, as well as the safety and ad-
verse events of these agents, should be considered in
addition to the results of the current NMA. Another
limitation is that the current case study was based on a
research question focused on the comparison of everoli-
mus versus chemotherapy. However, the original scope
of the research question as defined by NICE also inclu-
ded fulvestrant as a comparator of interest. A separate
NMA has been performed by Bachelot et al. in order to
address this comparison of interest among women with
ER+ ABC following progression or recurrence after
endocrine therapy [74]. Although ideally all of the
comparisons of interest should be included in one
simultaneous analysis, there is a clear justification for aseparate analysis in this case given the challenge of com-
paring everolimus to chemotherapy.
It should be noted that this feasibility process has
some limitations. In the initial stages (parts A and B) it
may not be necessary to extract the outcomes of interest
from all studies, thereby improving the efficiency of the
process. However, it is necessary to assess whether there
is a sufficient amount of information reported regarding
the outcome and its measure of uncertainty, which re-
quires decision rules regarding the calculation of treat-
ment differences or the estimates of uncertainty that may
be particularly challenging to define a priori for continu-
ous endpoints depending on the available information.
Similarly, if imputation will be used to assess uncertainty
measures, a threshold regarding the amount of missing in-
formation that will be permitted may be necessary. How-
ever, pre-specifying decision-rules for all possible types of
endpoints, including optimal thresholds for the amount of
data required for covariate analyses may be challenging.
Although some research has evaluated alternative imput-
ation methods for NMAs [75], to our knowledge alterna-
tive thresholds for missing data depending on the type of
outcome requires further research.
Although the current case study was based on a com-
plex network structure, in ‘star’ shaped networks, invol-
ving several trials with a common comparator (such as
placebo), we would emphasize the importance of asses-
sing whether differences in baseline risk exist and can be
adjusted (part C). A plot of the difference measure ver-
sus the baseline risk is useful to help illustrate the var-
iation in the baseline risk, as well as the relationship
between the difference and baseline risk for each treat-
ment. Even in cases where head-to-head trials are inclu-
ded in the network, it is possible to predict a placebo-arm
on the basis of the other trials [15].
The current framework suggests a separate process for
each outcome (and time point) of interest based on evi-
dence available from RCTs identified from a systematic
review regarding a comparative efficacy or safety question.
However, undergoing the outlined feasibility process is ex-
pected to be very time consuming, and it may be more
realistic to assess multiple outcomes in parallel, particu-
larly when they are related to the same endpoints or un-
derlying concepts. The case study explores the feasibility
of a NMA based on a synthesis of Kaplan Meier curves;
however, this process can be applied to any type of end-
points (that is, binary, continuous or rate outcomes). For
binary endpoints it may be important to consider whether
differences in follow-up are expected to act as a treatment
effect modifier and, if so, to what extent different follow-
up (or time points) can be combined. Similarly, for con-
tinuous outcomes, the range of time points at follow-up
than can be considered comparable should be clearly ad-
dressed. It may also be important to consider models that
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comes identified within the systematic review, particularly
in cases where the initial feasibility assessment suggests a
NMA may not be feasible. For example, in the context of
ABC, a multi-state model that accounts for PFS and
overall survival (as well as the relationship between the
outcomes) may provide more information (and possibly
more precision).
Another possible extension of the current process
would be to consider a broader evidence base if a net-
work is deemed not to be feasible. Depending on how
the research question was defined, it may be important
to assess whether additional indirect evidence may be
available by broadening the comparators of interest, al-
though this consideration should be offset by the risk of
introducing different populations in terms of the dis-
tribution of treatment effect modifiers. Similarly, it may
be possible to integrate non-randomized evidence using
more informative prior distributions [4] or individual pa-
tient data from RCTs [5,76-78] or non-randomized stu-
dies [79-81], which may influence the feasibility of an
analysis. Furthermore, it may be possible to elicit bias
distributions when there is insufficient data for a meta-
regression where experts provide information regarding
internal and external biases in order to adjust the study-
specific treatment effect [82] as cited in [20]. However,
these methods to combine multiple time points, outcomes
and study designs are evolving currently and require fur-
ther research. Therefore, the current process may provide
a useful starting point to identify the need for a more
complicated approach.Conclusions
In conclusion, the process outlined to assess the feasi-
bility of a NMA provides a stepwise framework that
will help to ensure that the underlying assumptions are
systematically explored and that the risks (and bene-
fits) of pooling and indirectly comparing treatment
effects from RCTs for a particular research question
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